The development of therapeutic antibodies against oncogenic antigens (Record no. 75920)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02179nim a2200517 a 4500 |
001 - CONTROL NUMBER | |
control field | HST8115 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | UkLoHST |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
fixed length control field | m o h |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nna|||||||| |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | sr |mnnnnnzne| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201004s2020 enk|||||o||h||||||||eng d |
028 50 - PUBLISHER NUMBER | |
Publisher number | 8115 |
Source | Henry Stewart Talks |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (UkLoHST)3776 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | UkLoHST |
Language of cataloging | eng |
Transcribing agency | UkLoHST |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Seon, Ben, |
Affiliation | (Roswell Park Cancer Institute, USA) |
Relator code | spk |
245 14 - TITLE STATEMENT | |
Title | The development of therapeutic antibodies against oncogenic antigens |
Medium | [electronic resource] / |
Statement of responsibility, etc. | an interview with Ben Seon. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Place of publication, distribution, etc. | London : |
Name of publisher, distributor, etc. | Henry Stewart Talks, |
Date of publication, distribution, etc. | 2020. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 1 online resource (1 streaming audio file (15 min.)). |
490 1# - SERIES STATEMENT | |
Series statement | Research and clinical interviews, |
International Standard Serial Number | 2056-452X |
500 ## - GENERAL NOTE | |
General note | Audio interview. |
500 ## - GENERAL NOTE | |
General note | Title from title frames. |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Contents: The development of naked and drug-conjugated antibodies against endoglin and CD75b -- The results of recent clinical trials with both therapeutic antibodies -- Advantages and challenges in the development of naked and drug-conjugated antibodies. |
506 ## - RESTRICTIONS ON ACCESS NOTE | |
Terms governing access | Access restricted to subscribers. |
538 ## - SYSTEM DETAILS NOTE | |
System details note | Mode of access: World Wide Web. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antibody-drug conjugates. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antineoplastic agents. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Cancer |
General subdivision | Immunotherapy. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Clinical trials. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Monoclonal antibodies |
General subdivision | Therapeutic use. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Tumor antigens. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antibodies, Monoclonal |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antibodies, Monoclonal |
General subdivision | pharmacology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antigens, CD. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antigens, Neoplasm |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antineoplastic Agents |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Antineoplastic Agents |
General subdivision | pharmacology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Clinical Trials as Topic. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Endoglin. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Immunoconjugates |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Immunoconjugates |
General subdivision | pharmacology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Neoplasms |
General subdivision | drug therapy. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Receptors, Cell Surface |
General subdivision | metabolism. |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Henry Stewart talks. |
Name of part/section of a work | Biomedical & life sciences collection. |
-- | Research and clinical interviews. |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://hstalks.com/bs/3776/">https://hstalks.com/bs/3776/</a> |
856 42 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://hstalks.com/bs/p/1102/">https://hstalks.com/bs/p/1102/</a> |
Materials specified | Series |
No items available.